Informed Consent Challenges in the UK Digital Era

Published on 21/12/2025

Navigating Informed Consent Challenges in the UK’s Digital Clinical Trial Era

Informed consent is the cornerstone of ethical clinical research, ensuring that participants understand the nature, risks, and benefits of a study before agreeing to take part. In the United Kingdom (UK), the digital transformation of clinical trials has introduced new complexities in obtaining and documenting informed consent. Remote recruitment, eConsent platforms, and decentralized models demand alignment with the Medicines and Healthcare products Regulatory Agency (MHRA), Health Research Authority (HRA), and General Data Protection Regulation (GDPR). Ethics committees, including Research Ethics Committees (RECs), play a central role in evaluating whether consent processes uphold participant rights, transparency, and comprehension. While digital tools have improved accessibility and efficiency, they have also created challenges related to participant comprehension, data security, and inclusivity across diverse populations.

This article explores the evolving challenges of informed consent in UK clinical trials within the digital era, highlighting regulatory frameworks, operational hurdles, and best practices for sponsors and investigators.

Table of Contents

Background and Regulatory Framework

MHRA Oversight of Informed Consent

MHRA inspections scrutinize informed consent processes to ensure they comply with ICH E6(R2) GCP. Digital platforms must demonstrate audit trails, data integrity, and proper authentication mechanisms.

HRA

and Ethics Committee Role

The HRA oversees ethical governance of consent procedures. RECs assess whether information is presented in clear, participant-friendly formats, whether digitally or on paper.

GDPR and Data Privacy

GDPR requires lawful processing of personal and health data, explicit consent for data use, and robust safeguards for digital storage and transmission.

Core Clinical Trial Insights: Informed Consent in the Digital Era

1. eConsent Platforms

eConsent systems enable remote enrollment and interactive educational modules. However, validation of comprehension and accessibility across patient groups remains a challenge.

2. Digital Comprehension Barriers

Older adults, non-native English speakers, and rural populations may face difficulties engaging with digital consent forms, requiring tailored solutions and hybrid models.

3. Inclusivity in Consent Processes

Ethics committees emphasize inclusivity, recommending multimedia tools, translations, and simplified content for underrepresented populations.

4. Cybersecurity Risks

Digital consent records must be secured against unauthorized access. MHRA and GDPR demand encryption, audit trails, and identity verification.

5. NHS Integration

NHS Trusts implementing digital consent must integrate systems with hospital electronic health records (EHRs) while preserving patient confidentiality.

6. Decentralized Trial Consent

In DCTs, obtaining consent remotely adds challenges in verifying identity, ensuring comprehension, and maintaining documentation integrity.

7. MHRA Inspection Findings

Recent MHRA inspections of digital consent trials identified:

Lack of verification of patient comprehension in eConsent systems
Insufficient validation of digital platforms
Weak CRO oversight of consent documentation
Inadequate REC updates on modified consent forms

Best Practices & Preventive Measures

Engage MHRA and HRA early when implementing eConsent systems.
Validate platforms for data integrity, audit trails, and cybersecurity.
Incorporate comprehension checks, quizzes, and multimedia explanations.
Adopt hybrid consent approaches to accommodate non-digital populations.
Train investigators, CROs, and site staff in ethical digital consent procedures.

Scientific and Regulatory Evidence

Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
ICH E6(R2) – Good Clinical Practice
MHRA guidance on eConsent and decentralized trials
GDPR – General Data Protection Regulation
HRA Transparency and Ethics Policies

Special Considerations

Informed consent challenges in the digital era vary across populations:

Pediatrics: Dual consent from parents/guardians and age-appropriate assent tools are mandatory.
Rare Diseases: Patients often require additional education and support due to complex study designs.
Oncology: Patients under physical and emotional stress may need extra assistance understanding digital forms.
Advanced Therapies: ATMP trials require highly detailed consent forms explaining risks, manufacturing, and follow-up.

When Sponsors Should Seek Regulatory Advice

When introducing novel eConsent technologies or digital identity verification tools.
If participant populations include vulnerable groups such as pediatrics or cognitively impaired adults.
When conducting multinational trials requiring alignment with EU and US consent rules.
If MHRA inspection findings raise concerns about consent documentation.
When cybersecurity risks are identified in eConsent systems.

FAQs

1. What is eConsent in UK clinical trials?

eConsent refers to digital methods of obtaining informed consent, often including multimedia and interactive features to improve comprehension.

2. How does MHRA regulate digital consent?

MHRA requires systems to maintain audit trails, authentication, and validation for data integrity and participant safety.

3. What challenges exist for digital consent?

Challenges include inclusivity for non-digital populations, comprehension validation, cybersecurity, and CRO oversight.

4. Are hybrid consent models used in the UK?

Yes, many sponsors combine digital and paper methods to accommodate diverse patient populations.

5. How does GDPR affect digital consent?

GDPR mandates explicit consent for data use, lawful processing, and strict security measures for digital records.

6. What are common MHRA inspection findings?

Insufficient comprehension validation, weak CRO oversight, and inadequate digital system validation are common issues.

7. How are ethics committees involved?

RECs review and approve consent processes, ensuring ethical compliance and transparency.

Conclusion

Informed consent remains a cornerstone of ethical research in the UK, but digital transformation has introduced new challenges. With MHRA, HRA, and GDPR requirements, sponsors must validate eConsent systems, maintain inclusivity, and uphold transparency. By engaging early with regulators, strengthening oversight, and adopting hybrid consent strategies, sponsors can protect participant rights while leveraging the benefits of digital innovation in clinical trials.